GPRC5D and Miyoshi myopathy: Similarly, a study of a small cohort of MM patients relapsing after a GPRC5D-targeted CAR T-cell therapy revealed diverse mechanisms of antigen loss or reduction: one-third of patients exhibited genetic deletions, while the majority showed hypermethylation affecting the transcriptional regulation of GPRC5D [53].